Currently Viewing:
Newsroom
Currently Reading
Headache Disorders Play Significant Role in Disability Globally and Require More Attention, Study Finds
December 12, 2018 – Alison Rodriguez
Pennsylvania Auditor General Calls for Action on PBMs
December 12, 2018 – Allison Inserro
Diet Has Minimal Association With Breast Cancer Risk in Postmenopausal Women, Study Finds
December 12, 2018 – David Bai, PharmD
Myelofibrosis Survival After Discontinuing Ruxolitinib Differs Based on Reason for Discontinuation
December 12, 2018 – Jaime Rosenberg
What We're Reading: Bill Targets Maternal Mortality Rates; Cutting Drug Prices; US Biosimilar Adoption
December 12, 2018 – AJMC Staff
What We're Reading: High Court Lets Abortion Cases Stand; NIH and Fetal Tissue; Dsuvia Examined
December 11, 2018 – AJMC Staff
Durvalumab Combination Fails to Meet Primary End Point in NSCLC Trial
December 11, 2018 – Samantha DiGrande
Rate of Uninsured Increased in 2017 for the First Time Since 2014
December 11, 2018 – Allison Inserro
More Than 300 Groups Seek Halt to CMS' Plans for Global Drug Pricing Index
December 10, 2018 – Allison Inserro

Men With Advanced Cancers Respond Better Than Women to Immune Checkpoint Inhibitors

Samantha DiGrande
A recent systematic review and meta-analysis published in The Lancet Oncology found that men with advanced cancers respond better than women to treatment with anti-PD-1 or anti-CTLA-4 immune checkpoint inhibitors.
A recent systematic review and meta-analysis published in The Lancet Oncology found that men with advanced cancers respond better than women to treatment with anti-PD-1 or anti-CTLA-4 immune checkpoint inhibitors.

Researchers identified 20 eligible randomized controlled trials of immune checkpoint inhibitors (ipilimumab, tremelimumab, nivolumab, or pembrolizumab) that reported overall survival according to patients’ sex. The 20 randomized trials were comprised of a total of 11,351 patients with advanced or metastatic cancers (7646 [67%] men and 3705 [32%] women).

The pooled overall survival hazard ratio (HR) was 0.72 (95% CI 0.65-0.79), or 28% lower risk of death in male patients treated with immune checkpoint inhibitors, compared with men treated standard therapies in control groups. In women treated with immune checkpoint inhibitors, the pooled overall survival was 0.86 (95% CI 0.79-0.93), or 14% lower risk of death compared with control groups. Researchers identified that the difference in efficacy between men and women treated with immune checkpoint inhibitors was significant, P = .0019.

“Immune checkpoint inhibitors can improve overall survival for patients with advanced cancers such as melanoma and non-small cell lung cancer, but the magnitude of benefit is sex-dependent. The pooled reduction of risk of death was double the size for male patients than for female patients,” noted the study authors. 

Based on these findings, the authors have recommended that a patient’s sex “should be taken into account in the assessment of risk versus benefit when making decisions about treatment strategies.”

Future research should look to optimize immunotherapies for female patients, and clinical trials should strive to include more women to better ensure they capture a potential therapies’ effectiveness more effectively.

As “immune checkpoint inhibitors are associated with specific adverse events, efforts are ongoing to identify predictive biomarkers” that may be able to identify patients that are most likely to “derive the maximum benefit” from a specific treatment. These efforts must be aware of “sex-related differences in the benefit[s] achievable from immunotherapies.” However, to date it “remains an under-investigated issue.”

Reference

Conforti F, Pala L, Bagnardi V, et al. Cancer immunotherapy efficacy and patients’ sex: a systematic review and meta-analysis [published online May 16, 2018]. Lancet Oncol. doi.org/10.1016/S1470-2045(18)30261-4

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!